$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000143774918020578 Filed on November 13, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$2.030M	$2.020M	$2.071M
YoY Change	6.28%	-2.46%	-61.07%
Cost Of Revenue	$1.470M	$1.477M	$3.274M
YoY Change	-15.03%	-54.89%	-12.46%
Gross Profit	$560.0K	$543.0K	-$1.203M
YoY Change	211.11%	-145.14%	-176.62%
Gross Profit Margin	27.59%	26.88%	-58.09%
Selling, General & Admin	$4.960M	$4.499M	$4.928M
YoY Change	5.76%	-8.71%	-47.63%
% of Gross Profit	885.71%	828.55%
Research & Development	$1.670M	$1.404M	$2.322M
YoY Change	-15.66%	-39.53%	-35.32%
% of Gross Profit	298.21%	258.56%
Depreciation & Amortization	$540.0K	$220.0K	$310.0K
YoY Change	68.75%	-29.03%	-24.39%
% of Gross Profit	96.43%	40.52%
Operating Expenses	$6.630M	$5.903M	$7.666M
YoY Change	-0.6%	-23.0%	-41.08%
Operating Profit	-$6.070M	-$5.360M	-$8.869M
YoY Change	-6.47%	-39.56%	-22.47%
Interest Expense	-$260.0K	$324.0K	$1.599M
YoY Change	-83.33%	-79.74%	-203.83%
% of Operating Profit
Other Income/Expense, Net	$240.0K	$242.0K
YoY Change
Pretax Income	-$6.090M	-$5.390M	-$10.44M
YoY Change	-40.0%	-48.37%	-19.51%
Income Tax
% Of Pretax Income
Net Earnings	-$6.090M	-$5.388M	-$10.44M
YoY Change	-40.0%	-48.41%	-19.48%
Net Earnings / Revenue	-300.0%	-266.73%	-504.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.683M	-$4.812M	-$174.0M
COMMON SHARES
Basic Shares Outstanding	23.46M
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.41M	$10.01M	$10.17M
YoY Change	204.45%	-1.57%	-76.5%
Cash & Equivalents	$16.41M	$10.01M	$10.17M
Short-Term Investments
Other Short-Term Assets	$640.0K	$730.0K	$880.0K
YoY Change	0.0%	-17.05%	14.29%
Inventory	$3.422M	$3.450M	$5.050M
Prepaid Expenses
Receivables	$1.154M	$1.460M	$1.200M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.62M	$15.65M	$17.29M
YoY Change	88.81%	-9.49%	-69.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.078M	$2.065M	$3.460M
YoY Change	-29.56%	-40.32%	-21.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$584.0K	$220.0K
YoY Change		165.45%	4.76%
Total Long-Term Assets	$2.078M	$2.649M	$3.680M
YoY Change	-42.86%	-28.02%	-20.17%
TOTAL ASSETS
Total Short-Term Assets	$21.62M	$15.65M	$17.29M
Total Long-Term Assets	$2.078M	$2.649M	$3.680M
Total Assets	$23.70M	$18.30M	$20.97M
YoY Change	57.07%	-12.74%	-65.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.148M	$2.158M	$840.0K
YoY Change	-9.82%	156.9%	-36.84%
Accrued Expenses	$1.449M	$577.0K	$3.550M
YoY Change	-59.72%	-83.75%	-37.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.490M	$8.150M	$43.11M
YoY Change	-83.26%	-81.09%
Total Short-Term Liabilities	$14.20M	$13.95M	$47.51M
YoY Change	-71.87%	-70.64%	581.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$41.00K	$187.0K	$180.0K
YoY Change	-86.38%	3.89%	-78.57%
Total Long-Term Liabilities	$41.00K	$187.0K	$180.0K
YoY Change	-86.38%	3.89%	-99.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.20M	$13.95M	$47.51M
Total Long-Term Liabilities	$41.00K	$187.0K	$180.0K
Total Liabilities	$14.24M	$14.14M	$47.68M
YoY Change	-71.96%	-70.35%	-1.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$328.9M	-$322.8M
YoY Change	9.15%
Common Stock	$338.3M	$327.0M
YoY Change	27.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.460M	$4.162M	-$26.71M
YoY Change
Total Liabilities & Shareholders Equity	$23.70M	$18.30M	$20.97M
YoY Change	57.07%	-12.74%	-65.3%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$6.090M	-$5.388M	-$10.44M
YoY Change	-40.0%	-48.41%	-19.48%
Depreciation, Depletion And Amortization	$540.0K	$220.0K	$310.0K
YoY Change	68.75%	-29.03%	-24.39%
Cash From Operating Activities	-$4.030M	-$3.090M	-$6.990M
YoY Change	-22.2%	-55.79%	-36.91%
INVESTING ACTIVITIES
Capital Expenditures	$380.0K	-$280.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$30.00K	$0.00
YoY Change
Cash From Investing Activities	$380.0K	-$250.0K	$10.00K
YoY Change		-2600.0%	-107.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.05M	3.210M	3.190M
YoY Change	2412.5%	0.63%	-90.05%
NET CHANGE
Cash From Operating Activities	-4.030M	-3.090M	-6.990M
Cash From Investing Activities	380.0K	-250.0K	10.00K
Cash From Financing Activities	10.05M	3.210M	3.190M
Net Change In Cash	6.400M	-130.0K	-3.790M
YoY Change	-233.89%	-96.57%	-118.19%
FREE CASH FLOW
Cash From Operating Activities	-$4.030M	-$3.090M	-$6.990M
Capital Expenditures	$380.0K	-$280.0K	$0.00
Free Cash Flow	-$4.410M	-$2.810M	-$6.990M
YoY Change	-14.86%	-59.8%	-36.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	avgr	Accrued Offering Costs AccruedOfferingCosts	187000
	avgr	Accrued Offering Costs AccruedOfferingCosts
CY2016Q1	avgr	Common Stock Offering Maximum Aggregate Value CommonStockOfferingMaximumAggregateValue	1500000
CY2015Q3	avgr	Debt Instrument Cash Payment Of Interest Minimum Percentage DebtInstrumentCashPaymentOfInterestMinimumPercentage	0.085
CY2015Q3	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	5000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	2500000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	3500000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall	2
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue After Year Five DebtInstrumentCovenantComplianceTargetMinimumRevenueAfterYearFive	70000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Eighth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueEighthYear	25000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fifth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFifthYear	60000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue First Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFirstYear	7000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fourth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear	50000000
CY2016Q4	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	18000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	23000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Seventh Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSeventhYear	20000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Sixth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSixthYear	15000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Third Year DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear	40000000
CY2015Q3	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.07
CY2018Q1	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2015Q3	avgr	Debt Instrument Financing Fee Percentage DebtInstrumentFinancingFeePercentage	0.015
CY2015Q3	avgr	Debt Instrument Maximum Percentage Of Interest Convertible Into Additional Loans DebtInstrumentMaximumPercentageOfInterestConvertibleIntoAdditionalLoans	0.04
CY2015Q3	avgr	Debt Instrument Period For Interest And Principal Payments DebtInstrumentPeriodForInterestAndPrincipalPayments	P2Y
CY2015Q3	avgr	Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage	0.01
CY2015Q3	avgr	Debt Instrument Redemption Initial Prepayment Premium Percentage DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage	0.05
CY2015Q3	avgr	Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear	0
	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment
	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment	158000
	avgr	Dividends Declared But Not Yet Paid DividendsDeclaredButNotYetPaid	2082000
	avgr	Dividends Declared But Not Yet Paid DividendsDeclaredButNotYetPaid
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-115000
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-381000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	5330000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	1649000
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest	60000
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5216000
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2018Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2017Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	15534000
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts	3539000
	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts	3187000
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	333000
CY2017Q4	avgr	Sale Of Stock Number Of Shares Under Registration Statement SaleOfStockNumberOfSharesUnderRegistrationStatement	248750
CY2017Q4	avgr	Sale Of Stock Obligation Period SaleOfStockObligationPeriod	P2Y180D
CY2017Q4	avgr	Sale Of Stock Potential Maximum Consideration SaleOfStockPotentialMaximumConsideration	15000000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	103000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	24000
	avgr	Warranty Period WarrantyPeriod	P1Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23458153
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2158000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1273000
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1460000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1127000
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	577000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3597000
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	326947000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	265636000
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	191000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	146000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	87000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	186000
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19650979
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2228481
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15234222
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2203165
CY2018Q3	us-gaap	Assets Assets	18298000
CY2017Q4	us-gaap	Assets Assets	15088000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	15649000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	11451000
CY2018Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10008000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5389000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36096000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10170000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4619000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25926000
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11554149
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	833597
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11554149
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	833597
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	10000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	1477000
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	3274000
	us-gaap	Cost Of Revenue CostOfRevenue	5061000
	us-gaap	Cost Of Revenue CostOfRevenue	11268000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	219000
CY2018Q3	us-gaap	Interest Expense InterestExpense	324000
CY2017Q3	us-gaap	Interest Expense InterestExpense	1599000
	us-gaap	Interest Expense InterestExpense	5358000
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	38000000
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1
CY2015Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.125
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	735000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1162000
CY2018Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	2082000
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-17.20
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-64.30
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	986000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	863000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y164D
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	971000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2979000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2017Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	28000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2018Q3	us-gaap	Gross Profit GrossProfit	543000
CY2017Q3	us-gaap	Gross Profit GrossProfit	-1203000
	us-gaap	Gross Profit GrossProfit	826000
	us-gaap	Gross Profit GrossProfit	-3247000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	297000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-766000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	378000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2270000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2618000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-896000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	123000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1406000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-776000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1789000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-104000
	us-gaap	Operating Expenses OperatingExpenses	17063000
	us-gaap	Operating Expenses OperatingExpenses	30712000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5120000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8869000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16237000
	us-gaap	Interest Expense Debt InterestExpenseDebt	3800000
	us-gaap	Interest Paid Net InterestPaidNet	60000
	us-gaap	Net Income Loss NetIncomeLoss	-21468000
	us-gaap	Net Income Loss NetIncomeLoss	-38582000
	us-gaap	Interest Expense InterestExpense	4720000
	us-gaap	Interest Paid Net InterestPaidNet	3637000
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2176000
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3009000
CY2018Q3	us-gaap	Inventory Net InventoryNet	3450000
CY2017Q4	us-gaap	Inventory Net InventoryNet	4295000
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	879000
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1286000
CY2018Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	395000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
	us-gaap	Inventory Write Down InventoryWriteDown	630000
	us-gaap	Inventory Write Down InventoryWriteDown	5180000
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	54000
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	137000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	88000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	106000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2018Q3	us-gaap	Liabilities Liabilities	14136000
CY2017Q4	us-gaap	Liabilities Liabilities	50778000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18298000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15088000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13949000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50477000
CY2015Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “OCT”) </div>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialization of Pantheris, the Company’s image-guided atherectomy system, designed to allow physicians to precisely remove arterial plaque in PAD patients. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>the Company also received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(K) clearance from the FDA for its next generation of Pantheris, Pantheris <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0.</div> The Company has sales in the U.S. and select international markets. The Company is located in Redwood City, California. The Company submitted a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) filing in respect of Pantheris SV, a lower profile Pantheris, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018 </div>and received CE Marking approval for Pantheris SV in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company adopted Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div><div style="display: inline; font-style: italic;">, Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>),</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> which requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date of the issuance of these financial statements. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company had an accumulated deficit of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$322.8</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.0</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> together with net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.1</div> million from its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>public offering and expected revenues will be sufficient to allow the Company to fund its current operations through at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019. </div>The Company will seek additional sources of funding in the form of debt financing or equity issuances, however, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> invoked the material adverse change clause. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it converted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38,000,000</div> of the outstanding principal amount of its senior secured term loan into a newly authorized Series A preferred stock.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company filed a universal shelf registration statement to offer up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150,0000</div> of its securities and entered into an “at-the-market” program pursuant to a Sales Agreement with Cowen and Company (“Cowen”), through which it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>from time to time, issue and sell shares of common stock having an aggregate offering value of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50,000,000.</div> The shelf registration statement also covers the resale of the shares sold to CRG in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The registration statement was declared effective by the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div></div></div>shares of common stock through the “at-the-market” program. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$75</div> million from issuing securities under a shelf registration statement in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> of such company’s public float in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period, the Company is unable to issue more shares in its “at-the-market” program at this time.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979</div> shares of Series B convertible preferred stock (the “Series B preferred stock”). As a result, the Company received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.0</div> million after underwriting discounts, commissions, legal and accounting fees of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div>).</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park is obligated to purchase, at the Company’s request, up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000,000</div> of the Company’s common stock over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div>-month period, subject to certain limitations set forth in the agreement (the “Lincoln Park Purchase Agreement”). As a fee for Lincoln Park’s commitment to purchase such shares, the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,584</div> shares of common stock to Lincoln Park on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> As obligated under a registration rights agreement entered into with Lincoln Park in connection with the Purchase Agreement, the Company filed a registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> for up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">248,750</div> of such shares, which registration statement was declared effective by the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Since <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we have sold an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65,000</div> shares of our common stock under the Lincoln Park Purchase Agreement for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.5</div> million of gross proceeds.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company filed a prospectus supplement to offer <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,166,180</div> shares of its common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.6425</div> per share, for net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million after deducting placement agent fees of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$285,000</div> and expenses of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>the Company completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,285,000</div><div style="display: inline; text-decoration: underline;"> </div>shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, the Company received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.1</div> million after underwriting discounts, commissions, legal and accounting fees of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19439000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3414000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-383000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14437000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29299000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-5388000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-10443000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6224000
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10443000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28766000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38582000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	5663000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7666000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33959000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1279000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1009000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	270000
CY2018Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	241000
	us-gaap	Profit Loss ProfitLoss	-21468000
	us-gaap	Profit Loss ProfitLoss	-38582000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2065000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2950000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	45000
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	506000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	721000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1519000
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	584000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	687000
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	187000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	301000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9000
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	155000
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	411000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000
CY2018Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	836000
CY2017Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2082000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	43501
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	43501
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	731000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	640000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	246000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	28000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	581000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	390000
CY2018Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	339000
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	282000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	104000
CY2018Q3	us-gaap	Purchase Obligation PurchaseObligation	1.80
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	19000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1404000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2322000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4340000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9342000
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	416000
	us-gaap	Restructuring Charges RestructuringCharges
	us-gaap	Restructuring Charges RestructuringCharges	935000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-322795000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301327000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2020000
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2071000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5887000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8021000
CY2018Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	8146000
CY2017Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	44744000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	4162000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-35690000
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4259000
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4928000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12723000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20435000
	us-gaap	Share Based Compensation ShareBasedCompensation	2028000
	us-gaap	Share Based Compensation ShareBasedCompensation	4197000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	23300
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	31000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76645
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	84345
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	291.73
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	193.88
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	260.02
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.67
CY2018Q3	us-gaap	Share Price SharePrice	1.32
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	23584
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div></div></div></div></div></div></div></div>
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11194000
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	607000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6691000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	600000
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0

Files In Submission

Name	View Source	Status
0001437749-18-020578-index-headers.html	Edgar Link	pending
0001437749-18-020578-index.html	Edgar Link	pending
0001437749-18-020578.txt	Edgar Link	pending
0001437749-18-020578-xbrl.zip	Edgar Link	pending
avgr-20180930.xml	Edgar Link	completed
avgr-20180930.xsd	Edgar Link	pending
avgr-20180930_cal.xml	Edgar Link	unprocessable
avgr-20180930_def.xml	Edgar Link	unprocessable
avgr-20180930_lab.xml	Edgar Link	unprocessable
avgr-20180930_pre.xml	Edgar Link	unprocessable
avgr20180930_10q.htm	Edgar Link	pending
ex_128603.htm	Edgar Link	pending
ex_128604.htm	Edgar Link	pending
ex_128605.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2018 Q4 Form 10-Q Financial Statement

#000143774918020578 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2018 Q4 Form 10-Q Financial Statement

#000143774918020578 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr